Summary

The optimal duration of treatment with fluoropyrimidines (FPs), oxaliplatin (OX), and bevacizumab (BEV) for patients with metastatic colorectal cancer (mCRC) is not known. This article presents results from the phase 3 study Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC) [AIO KRK 0207; NCT00973609]. This trial investigated maintenance chemotherapy with FPs+BEV, BEV alone, or no treatment following a 24-week first-line induction with FPs, OX, and BEV for patients with mCRC.